Researchers from the Hong Kong Polytechnic University have developed an intelligent biosensing platform that revolutionizes point-of-care tumor marker detection. Combining luminescent nanoparticles, a microfluidic biochip, and machine vision algorithms, this portable system achieves exceptional sensitivity for detecting biomarkers like carcinoembryonic antigen (CEA) in saliva samples. Published in Nano-Micro Letters, this breakthrough could transform early cancer screening and monitoring.
Led by Professor Jianhua Hao, the team created a sandwich-structured immunoassay using quantum dots as optical labels. These nanoparticles, modified with antibodies, bind to target biomarkers in saliva. The microfluidic biochip then separates and concentrates the biomarkers, while a machine vision algorithm analyzes luminescent signals captured under UV light—all integrable with a smartphone for rapid results.
Key advantages include:
- Unmatched Sensitivity: The platform detects CEA at concentrations as low as 0.021 ng/mL, outperforming commercial lateral flow assays.
- Noninvasive Testing: Saliva samples eliminate the need for blood draws, reducing patient discomfort and risk.
- Portability: The compact design and smartphone compatibility make it ideal for clinics and remote settings.
In validation tests using artificial saliva, the system demonstrated high specificity for CEA, underscoring its clinical potential.
Dr. Hao emphasized, “This technology bridges the gap between lab-grade accuracy and point-of-care convenience, offering a scalable solution for early cancer detection.”
The platform’s innovative design paves the way for accessible, high-precision cancer diagnostics. Future research may expand its capabilities to detect additional biomarkers, further advancing personalized healthcare.
Add comment